The content on this site is intended for healthcare professionals only
Dr Jacob Adashek speaks to ecancer about his work involving genomic alterations and immune regulatory molecule expression patterns.
He comments on trends in strategies of cancer care around using combinations of targeted and immune therapies, and highlights the importance of being able to predict the outcomes of these therapies.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
EAU 2024: Bladder cancer latest
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Updates on lung cancer from WCLC and ESMO 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
